Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

RecruitingOBSERVATIONAL
Enrollment

190

Participants

Timeline

Start Date

October 6, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
CancerPancreatic Cancer
Interventions
PROCEDURE

Tumour Biopsy

If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.

OTHER

Serial Collection of Plasma and Serum Samples

Participants will undergo serial collection of plasma and serum samples at baseline and every cycle of chemotherapy or every 4 weeks, whichever is longer, until end of study.

Trial Locations (4)

T2N 4N2

RECRUITING

Tom Baker Cancer Centre, Calgary

T6G 1Z2

WITHDRAWN

Cross Cancer Institute, Edmonton

V5Z 4E6

RECRUITING

BC Cancer - Vancouver, Vancouver

K1H 8L6

ACTIVE_NOT_RECRUITING

The Ottawa Hospital, Ottawa

All Listed Sponsors
collaborator

Terry Fox Research Institute

OTHER

collaborator

BC Cancer Foundation

OTHER

collaborator

Pancreas Centre BC

OTHER

collaborator

American Society of Clinical Oncology

OTHER

lead

British Columbia Cancer Agency

OTHER

NCT02869802 - Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis | Biotech Hunter | Biotech Hunter